SAGE Therapeutics
Sage Therapeutics focuses on developing innovative medicines for brain health disorders, including postpartum depression, major depressive disorder, and neurodegenerative diseases. Their distinct approach integrates patient perspectives and emphasizes modulation of GABA and NMDA receptor systems.
Company Overview
SAGE Therapeutics is committed to developing innovative medicines aimed at addressing brain health disorders. Their distinctive approach to neuroscience drug development involves integrating patient and care partner perspectives and the modulation of GABA and NMDA receptor systems.
Products
SAGE Therapeutics has brought unique treatments to market, including ZURZUVAE™ (zuranolone) CIV and ZULRESSO® (brexanolone) CIV. ZURZUVAE™ became available in 2023 as the first and only oral, 14-day treatment for adults with postpartum depression. ZULRESSO® is an FDA-approved injection for postpartum depression, first introduced in 2019 for patients aged 15 years and older.
Development Pipeline
SAGE Therapeutics is advancing an extensive pipeline focused on brain health disorders, including major depressive disorder, Huntington’s disease cognitive impairment, Alzheimer's disease mild cognitive impairment and mild dementia, and essential tremor. Their investigational compound dalzanemdor (SAGE-718) is being explored for neurodegenerative and neuropsychiatric disorders.
Partnerships
SAGE Therapeutics collaborates with Biogen Inc. for the development of SAGE-324 and zuranolone. Additionally, they have a collaboration and license agreement with Shionogi covering zuranolone in Japan, Taiwan, and South Korea. These partnerships aim to broaden their impacts on brain health treatments.
Research and Development
SAGE Therapeutics applies a translational research strategy focusing on the modulation of GABA and NMDA receptors, critical for CNS function regulation. Their compounds aim to modulate activity within these receptor systems, enhancing the understanding and treatment of brain health disorders.